The second listed company in the pharmaceutical manufacturing industry reported a successful counter-attack in the third quarter

"Pharmaceutical network industry dynamics" a few days ago, A-share three-quarter report disclosure has begun.
October 13, Erkang Pharmaceuticals, the second listed company in the pharmaceutical manufacturing industry, released its third-quarter 2020 report, the first three-quarter report for Xiang shares this year.
the first three quarters of this year, the company reported a net profit of 181 million yuan, up 9.89 percent year-on-year, exceeding its full-year 2019 net profit.
, the company achieved net profit attributable to 115 million yuan in the third quarter, up 221.56 percent year-on-year.
's 2020 semi-annual report shows that due to the special period and the reform of the pharmaceutical system, the company's first-half results were staminy, recovered rapidly in the second quarter, and revenue returned to growth. during the
reporting period, the Company achieved operating income of RMB1.202 billion and net profit of RMB66.1527 million, of which revenue in the second quarter was RMB761 million, up 27.42% YoY, and net profit was RMB42.46 million, basically the same as in the same period last year.
that its third-quarter report was a successful counter-attack, meaning the company is on track to return to growth.
addition, the third-quarter report shows that the production project of Phoenix Industrial Limited Erkang Pharmaceutical Intermediates in Cambodia, launched in the second half of 2018, has been completed on schedule and has been put into trial operation.
The project investment estimate of 95 million yuan, the main products for nitrophenol, ammonia phenol, etc. , the smooth implementation of the project is expected to further reduce the cost of RAW drugs, to ensure the continued and stable supply of raw materials, while further reducing raw material costs, to enhance the competitiveness of enterprises.
the same time, in May 2020, Phoenix Industrial, a wholist, used a self-financing fund of RMB18,040.25 million to invest in cambodia to build an annual output of 10,000 tons of aniline.
project construction, is conducive to the company to enrich the product line, extend the API industry chain, further reduce the company's API production costs, to ensure the stable supply of API intermediates.
the end of the reporting period, the project had completed an investment of 17,755.10 million yuan.
end of September this year, Erkang Pharmaceuticals also signed a strategic cooperation agreement with Guangzhou Chemical, a subsidiary of Guangzhou Light Industry Group, and the two sides intend to carry out in-depth cooperation in the fields of pharmaceutical intermediates and API.
the latter is an integrated modern trading company integrating import and export, domestic trade and warehousing business, which is expected to use its strong channel advantages to help Erkang Pharmaceuticals improve the market penetration of its products.
addition to the layout of pharmaceutical intermediates, API fields, Erkang Pharmaceuticals also promote the development of new Chinese medicine, hospital terminal development and drug promotion work.
July 2020, the company and Hunan Hengtian Pharmaceutical Technology Co., Ltd. jointly set up Hunan Juzhi Pharmaceutical Technology Co., Ltd., the company paid 21 million yuan of registered capital, accounting for 70%.
has also completed the business registration procedures.
in the expansion of production capacity, channels at the same time, Erkang Pharmaceuticals is also constantly enriching its own product category reserves.
In the first half of this year, Erkang Pharmaceutical added 15 new raw material drug species, focusing on the development of strategically important raw materials products, especially the focus on the layout of anti-epidemic-related varieties, the company through acquisition, resource integration and other means, the addition of 20 New Chinese medicine approvals, including ten-flavored hand ginseng, eight-flavored fennel pills, glycerine ghee pills, which also means that the company in the Chinese medicine business layout has taken an important step.
understood that the company is steadily advancing the raw materials and pharmaceutical accessories industry chain extension layout, and actively build "raw materials and preparations" integrated production and marketing commercial ecology.
Relying on adequate financial support, the company actively adjust the product structure, fully tap the advantages of raw materials and pharmaceutical accessories resources, expand the layout of finished pharmaceutical business, in order to meet the industry "shuffle" brought about by the opportunities and challenges, in the market competition to seize the opportunity.